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Abstract
Background: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing
to small studies and lack of proper study design.
Methods: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July
2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for
childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity,
and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT
duration on pancreatic cancer development was calculated using multivariable Poisson regression.
Results: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-
users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had
a 23% reduced risk (OR 0.77; 95% CI: 0.68–0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR)
0.65; 95% CI: 0.33–1.27) in women who used MHT 1–2 years and by 60% (IRR 0.40; 95% CI: 0.18–0.88) in women who used
MHT 3 years compared to women with <1 year of MHT use. The type of MHT did not change the results.
Conclusion: Systemic MHT use might reduce the risk of pancreatic cancer.
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Background
Pancreatic cancer is the fourth leading cause of cancer
death in the world.1 The tumor is often diagnosed at an
advanced stage without possibility of surgery with cura-
tive intent owing to unspeciﬁc symptoms and late clin-
ical presentation.2 Even after surgery the prognosis
remains poor with 5-year survival rates below 20%
for the majority of patients.3
Cigarette smoking, high bodymass index, particularly
during early adulthood, and diabetes mellitus are known
risk factors for pancreatic cancer.4–7 The eﬀect of sex hor-
mones, particularly estrogens, has been a matter of
debate. It is known that women are less likely to develop
pancreatic cancer and this is not fully explained by the
diﬀerences in exposure to the known risk factors. Both
normal andneoplastic pancreatic tissues express estrogen
and progesterone receptors.8 Estrogen has been reported
to inhibit pancreatic cancer cell growth in experimental
studies.9–11 Thus, it is plausible that sex hormones might
aﬀect the risk of pancreatic cancer in women.
Several epidemiological studies have assessed the
role of hormonal factors, including menopausal hor-
mone therapy (MHT) in postmenopausal women, in
the development of pancreatic cancer.12–22 None of
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the case-control studies found any association between
MHT use and pancreatic cancer.13,14,17,18,22 However,
most case-control studies were hampered by a
non-random control selection, i.e. controls were
patients treated for non-neoplastic conditions in the
same hospital where pancreatic cancer patients received
treatment,13,14,17,22 or control selection by random digit
dialing.18 The results of the cohort studies have been
inconclusive.12,15,16,19–21 However, only one recent
study, with detailed information of MHT use, showed
a statistically signiﬁcantly 30% reduced risk of pancre-
atic cancer MHT users compared to non-user.12
Our aim was to conduct a large population-based
matched cohort design to study the association between
systemic MHT use and pancreatic cancer in Swedish
women using national population-based registers.
Methods
Study design
This study was a nationwide population-based matched
cohort study that included female residents in Sweden
older than 40 years without any history of cancer (not
including non-melanoma skin cancer) since 1 July 2005.
Subjects were followed up until occurrence of exocrine
pancreatic cancer, death or the end of follow-up in 31
December 2012. The Swedish Prescribed Drug Registry
was used to assess exposure to MHT before 1 January
2013. The Swedish Cancer Registry was used to identify
incident exocrine pancreatic cancer. History of diseases
and surgical procedures was retrieved from the Swedish
Patient Registry. Record linkage was made possible
using the Swedish National Identiﬁcation Number
which uniquely identiﬁes each Swedish resident.23 The
study was approved by the central ethical review board
in Stockholm, Sweden.
Sources of data
The Swedish Prescribed Drug Registry was established in
July 2005 and includes information on all prescribed and
dispended drugs in Sweden. The registry is complete for
the entire Swedish population (including only <0.3%
patient identity data for all items).24 Information on, rele-
vant drugs according to the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system, date of drug dis-
pensation, and mode of administration was collected.
The Swedish Cancer Registry has registered infor-
mation on all incident cases of cancer in Sweden since
1958. All cancers are recorded according to the
International Classiﬁcation of Diseases (ICD) codes
using the 7th and the current version of ICD.25
The Swedish Patient Registry was established in
1964 and since 1987 has national coverage on all
inpatient care and since 2001 national coverage on out-
patient specialist visits in Sweden.26 Each record
includes, among other data, information on discharge
diagnosis and surgical procedures.
The Cause of Death Registry has information on all
deceased Swedish residents since 1952 and data on
cause-speciﬁc death are 99.2% complete.27
Exposure identification
Women older than 40 years who received at least one
prescription of MHT (ATC codes: C03C for estrogens,
G03D for progestins, G03F for estrogen and proges-
tins) during the study period were identiﬁed
(n¼ 1,227,314). Exclusions were made for non-systemic
use of MHT (n¼ 529,868), MHT prescription after 31
December 2012 (n¼ 86,816), prescription of progestins
without concomitant prescription of estrogen
(n¼ 283,333), age< 40 years at time of ﬁrst MHT pre-
scription (considered as premature menopause or other
indications for MHT) (n¼ 18,739), and previous malig-
nant cancer excluding non-melanoma skin cancer
(n¼ 18,372). In total, there were 290,186 women
exposed to systemic MHT, i.e. oral or transdermal
administration route.
Women older than 40 years not receiving any MHT
medication during the study period were identiﬁed
(n¼ 2,281,118). Exclusions were made for previous his-
tory of malignant cancer excluding non-melanoma skin
cancer (n¼ 171,020).
Matching procedure
All women exposed to systemic MHT were randomly
matched to three unexposed women. Since the
matching was a computationally intensive procedure,
we decided to stratify the dataset ﬁrst, in eﬀect
making this an exact matched sample for the strat-
ifying variables and a nearest neighbor matched
sample for the other variables. Three stratifying vari-
ables, i.e. childbirth, history of thromboembolic
events, and previous hysterectomy, were initially
used to create eight strata of data. Within each of
these strata we matched on the nearest neighboring
control for year of birth, diabetes, obesity, smoking-
related- or alcohol-related disorders. Information on
history of diseases and previous hysterectomy
was retrieved using the Swedish Patient Register (a
complete list of ICD and surgical procedure codes is
available in the Appendix, supplied as a
Supplementary online ﬁle).
The matching procedure was based on group-level
matching and not individual matching. Thus, no index
date could be calculated for the unexposed matched
women because of matching on a group level.
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Outcome
Using the Swedish Cancer Registry, patients with a
histologically veriﬁed diagnosis of exocrine pancreatic
cancer (ICD-10 code C250, C251, C252, C257, C258,
and C259) were identiﬁed. Endocrine pancreatic cancer
was excluded. Using the C24 World Health
Organization classiﬁcation of histology, the histology
code ‘‘096’’ was used to identify adenocarcinoma of
exocrine pancreatic cancer.
Statistical analyses
Conditional logistic regression was used to calculate
the risk of developing pancreatic cancer comparing
women exposed to MHT to matched unexposed
women (ever versus never use), expressed as odds
ratios (ORs) and 95% conﬁdence intervals (CIs).
The statistical analyses included, apart from the
exact matching variables (previous delivery, history
of thromboembolic events, and previous hysterec-
tomy), the nearest neighbor matching variables
(year of birth, diabetes, obesity, and smoking- or
alcohol-related disorders), osteoporosis, chronic pan-
creatitis, and chronic liver disease. The statistical
analyses were also stratiﬁed for the type of systemic
MHT, i.e. estrogen only or combined therapy with
estrogen and progestins.
Poisson regression was used to calculate adjusted
incidence rate ratios (IRRs) and the corresponding
95% CIs for the eﬀect of MHT use duration and
pancreatic cancer using <1 year of MHT use as the
reference. Duration of use was categorized in three
categories (<1 year, 1–2 years, and 3 years).
For this analysis, only MHT users since 1 January
2006 were included, so we can assume that the date
of the ﬁrst prescription during the study period is the
actual ﬁrst prescription. Pancreatic cancer cases devel-
oped within the ﬁrst year after initiation of MHT use
were excluded to avoid detection bias. The statistical
analyses were performed using Stata v.9.4 statistical
software (Stata Corp).
Results
The baseline characteristics of 290,186 ever-users of
MHT between 1 July 2005 and 31 December 2012
and 870,165 matched never-users are shown in
Table 1. The median age at the start of the study was
57 years among the both exposure groups (interquartile
range for ever users 52–66 years; interquartile range for
never user 50–66 years). In total, 40.6% (117,861 ever-
users; 353,282 never-users) had a recorded childbirth in
the Patient Registry, 13.9% (40,316 ever-users; 120,931
never-users) had experienced a thromboembolic event
and 17.9% had a record of hysterectomy (51,811 ever-
users; 155,138 never-users). The distribution of dia-
betes, obesity, smoking- or alcohol-related disorders,
osteoporosis, chronic pancreatitis, and chronic liver
disease were similar between both groups. Estrogen as
a single therapy was used in 135,988 (46.9%) women,
whereas 154,198 (53.1%) received a combination of
estrogen and progestins.
In total, 311 (0.11%) ever-users and 1220 (0.14%)
never-users developed pancreatic cancer.
Adenocarcinoma was the most common histology
type in both groups (nexposed¼ 254 (81.7%); nunex-
posed¼ 994 (81.5%)). In a multivariable adjusted
model, ever-users had a 23% reduced risk (OR 0.77;
95% CI: 0.68–0.87) of pancreatic cancer. The point
estimates did not change when the results were strati-
ﬁed for histology type (Table 2). The result remained
virtually unchanged when the analyses were stratiﬁed
for MHT regimen (OR 0.77; 95% CI: 0.65–0.90 women
using estrogen only, OR 0.80; 95% CI: 0.67–0.96 for or
a combination of estrogen and progestins compared to
never-users).
Table 1. Baseline characteristics of Swedish women older than 40
years of age in relation to their exposure to menopausal hormone
therapy (MHT) between 1 July 2005 and 31 December 2012.
MHT use
Ever-users
Matched
never-users
Total 290,186 870,165
Age at inclusion, median
(interquartile range)
57 (52–66) 57 (50–66)
Childbirth, n (%) 117,861 (40.6) 353,282 (40.6)
Comorbidities
Thromboembolic
events, n (%)
40,316 (13.9) 120,931 (13.9)
Hysterectomy, n (%) 51,811 (17.9) 155,138 (17.8)
Diabetes mellitus, n (%) 15,936 (5.5) 48,422 (5.6)
Obesity, n (%) 5146 (1.8) 15,526 (1.8)
Smoking-related
disease, n (%)
13,601 (4.7) 40,994 (4.7)
Alcohol-related
disease, n (%)
7293 (2.5) 21,455 (2.5)
Osteoporosis, n (%) 8256 (2.9) 22,764 (2.6)
Chronic pancreatitis, n (%) 511 (0.2) 1272 (0.2)
Chronic liver
disease, n (%)
1760 (0.6) 5788 (0.7)
Type of MHT
Estrogen only, (%) 135,988 (46.9) –
Estrogen and
progestins, (%)
154,198 (53.1) –
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The risk of pancreatic cancer decreased with increas-
ing duration of MHT use (Table 3). This risk decreased
by 35% (IRR 0.65; 95% CI: 0.33–1.27) in women who
used MHT 1–2 years and by 60% (IRR 0.40; 95% CI:
0.18–0.88) in women who used MHT 3 years com-
pared to women with <1 year of MHT use.
Stratiﬁcation for type of systemic MHT did not
change the associations markedly but the results lost
statistical precision.
Discussion
In this large population-based study, we observed a
statistically signiﬁcant reduced risk of pancreatic
cancer in women who used MHT. This association
became stronger by longer duration of MHT use. The
observed associations did not diﬀer with respect to the
type of systemic MHT.
The strengths of this study are the large population-
based design, the complete nationwide coverage of
Swedish national registries on the MHT exposure and
the outcome, and most importantly the accessibility of
the Swedish healthcare system to all Swedish citizens.
These advantages reduce selection bias and facilitate
generalizability of the results. The prospectively col-
lected data on both exposure and the outcome reduced
information bias. However, this study has some limita-
tions. There was no information on MHT use prior to 1
July 2005. Thus, we were neither able to investigate the
eﬀect of past use of MHT nor the eﬀect of longer dur-
ation of MHT use on the development of pancreatic
cancer. We also lack information on socioeconomic
status. Although the role of socioeconomic status on
the development of pancreatic cancer is uncertain,28
this factor can act as a proxy variable for unhealthy
living habits that might aﬀect the development of pan-
creatic cancer. However, because of universal access to
the healthcare system to all Swedish residents, it is unli-
kely that women were deprived from MHT use because
of their socioeconomic status. Furthermore, many of
the matching variables, e.g. smoking- or alcohol-related
diseases, will act as proxy variables for lifestyle habits.
Although the matching procedure ensured similar dis-
tribution in potential confounders, residual confound-
ing is possible since there was no individual data on
these important confounders. However, we observed a
gradually declining risk of pancreatic cancer by the
Table 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between menopausal hormone therapy (MHT) use and
the risk of pancreatic cancer in Swedish women.
Any MHT use Estrogen only
Estrogen and
progestins
Ever-users
(n¼ 290,196)
Never-users
(n¼ 870,165) OR (95% CI)a OR (95% CI)a OR (95% CI)a
Pancreatic cancer
Total, n (%) 311 (0.11) 1220 (0.14) 0.77 (0.68–0.87) 0.77 (0.65–0.90) 0.80 (0.67–0.96)
By histology
Adenocarcinoma, n (%) 254 (0.09) 994 (0.11) 0.77 (0.67–0.88) 0.75 (0.62–0.90) 0.83 (0.68–1.01)
Other, n (%) 57 (0.02) 226 (0.03) 0.77 (0.57–1.02) 0.84 (0.60–1.18) 0.64 (0.38–1.07)
aThe model was adjusted for childbirth (matching variable), hysterectomy (matching variable), thromboembolic events (matching variable), date of birth,
smoking-related diseases, alcohol-related diseases, obesity, diabetes, osteoporosis, chronic liver disease, and chronic pancreatic disease.
Table 3. Incidence rate ratios (IRRs) and 95% confidence intervals
(CIs) for the association between duration of menopausal hormone
therapy (MHT) use and pancreatic cancer in Swedish women since
1 January 2006.
Pancreatic cancer
Ever-users
(n)
Pancreatic
cancer (%) IRR (95% CIs)a
Any MHT use
Duration of MHT use (years)
<1 58,801 43 (0.07) 1 (Reference)
1–2 33,013 16 (0.05) 0.65 (0.33–1.27)
3 24,905 8 (0.03) 0.40 (0.18–0.88)
Estrogen only
Duration of MHT use (years)
<1 28,389 27 (0.10) 1 (Reference)
1–2 11,732 7 (0.06) 0.43 (0.15–1.25)
3 11,080 5 (0.05) 0.50 (0.18–1.35)
Estrogen and progestins
<1 30,412 16 (0.05) 1 (Reference)
1–2 21,281 9 (0.04) 0.91 (0.37–2.22)
3 13,827 2 (0.02) 0.43 (0.12–1.54)
aThe model was adjusted for childbirth (matching variable), hysterectomy
(matching variable), thromboembolic events (matching variable), date of
birth, smoking-related diseases, alcohol-related diseases, obesity, diabetes,
osteoporosis, chronic liver disease, and chronic pancreatic disease.
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duration of MHT use among women exposed to this
medication. It is unlikely that confounding by life-style
factors would fully explain these results. Thus, the dis-
tribution of residual confounding should be unrelated
to the exposure status, i.e. result in non-diﬀerential
misclassiﬁcation.
The association between MHT and pancreatic cancer
has been studied in several cohort studies.12,15,16,19–21
Whereas no association was found in many of the previ-
ous studies, one recent publication showed a decreased
risk of pancreatic cancer in users of MHT.12 This study
was based on the California Teachers Study, a cohort
study that enrolled over 118,000 women in 1995–1996.
Baseline characteristics were collected by self-administered
questionnaire. In agreement with our ﬁndings, MHT use
was shown to reduce the risk of pancreatic cancer by 30%
(hazard ratio 0.70; 95% CI: 0.54–0.91) in that study.
Furthermore, as also shown by our results, there were
no clear diﬀerences in the risk of pancreatic cancer in rela-
tion to the type of systemic MHT. This highlights the
potential protective eﬀect of estrogen in the pathogenesis
of pancreatic cancer. Because of lack of multiple measure-
ments, the impact of MHT use duration on the develop-
ment of pancreatic cancer could not be assessed in that
study. In our study, a duration 3 years of MHT was
strongly associated with a decreased risk of this cancer.
Estrogen and its metabolites have been reported to
inhibit pancreatic cancer cell growth in in vitro stu-
dies.9–11 2-Methoxyestradiol, a natural estrogen metab-
olite, has itself cytotoxic properties and potentiates the
cytotoxic properties of other chemotherapeutic com-
pounds.29 However, this combination is associated
with high toxicity resulting in death of experimental
animals.29 2-Methoxyestradiol could also inhibit
tumor cell growth in cell lines resistant to cytostatic
drugs.30 Thus, estrogen provided as MHT substitution
might induce chemoprevention in exposed women and
act protective against the development of pancreatic
cancer. This might explain the observed reduced risk
of pancreatic cancer after relatively few years of
MHT use in the current study.
In conclusion, systemic MHT use, irrespective of the
MHT type, was associated with decreased risk of pan-
creatic cancer. Further investigations are warranted to
assess if this potential risk reduction remains at long-
term after cessation of MHT use.
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